The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. (Q52777531)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

title

The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

main subject

acute myeloid leukemia

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

author name string

Ling Zhang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

Kathy L McGraw

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

David A Sallman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

publication date

14 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

volume

58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

1777-1790

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

Localization of gene for human p53 tumour antigen to band 17p13.

29 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

p53 and chemosensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Cancer progression and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Post-translational modification of p53 in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Live or let die: the cell's response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Novel targets and interaction partners of mutant p53 Gain-Of-Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The p53 pathway: positive and negative feedback loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Wnt/beta-catenin signaling: components, mechanisms, and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The p53/microRNA network in cancer: experimental and bioinformatics approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Mdm2-mediated ubiquitylation: p53 and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Mdm2 and MdmX partner to regulate p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The p53-mdm-2 autoregulatory feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Scission of the p53-MDM2 Loop by Ribosomal Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Clinical effect of point mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The genetic basis of myelodysplasia and its clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Clinical and pathological correlations of marrow PUMA and P53 expressions in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The classification of MDS: from FAB to WHO and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Deletion 5q MDS: molecular and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Molecular dissection of the 5q deletion in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Divorcing ARF and p53: an unsettled case

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-dependent checkpoint response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53-Dependent Ribosomal-Stress Checkpoint Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Inhibition of HDM2 and activation of p53 by ribosomal protein L23

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Ribosomal protein S27L is a direct p53 target that regulates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

MicroRNAs: target recognition and regulatory functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Ribosome defects in disorders of erythropoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q− syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Recent Advances in the 5q- Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Induction of myelodysplasia by myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

PP2A: The Achilles Heal in MDS with 5q Deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Erythropoietin receptor signaling is membrane raft dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Myeloid malignancies: mutations, models and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

A novel hierarchical prognostic model of AML solely based on molecular mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Clinical significance of P53 and Bcl-2 in acute myeloid leukemia patients of Eastern India

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Increased p53 protein expression as a potential predictor of early relapse after hematopoietic stem cell transplantation in children with acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Disruption of the 5S RNP-Mdm2 interaction significantly improves the erythroid defect in a mouse model for Diamond-Blackfan anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Induction of the 5S RNP-Mdm2-p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The Ribosomal Protein-Mdm2-p53 Pathway and Energy Metabolism: Bridging the Gap between Feast and Famine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

An ARF-Independent c-MYC-Activated Tumor Suppression Pathway Mediated by Ribosomal Protein-Mdm2 Interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Oncogenic Intra-p53 Family Member Interactions in Human Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Resuscitating Wild-Type p53 Expression by Disrupting Ceramide Glycosylation: A Novel Approach to Target Mutant p53 Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Targeting the nucleolus for cancer-specific activation of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The casein kinase 1 family: participation in multiple cellular processes in eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Casein kinase 1: Complexity in the family

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Regulation of p53-MDMX interaction by casein kinase 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Protein kinase CK1α regulates erythrocyte survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2016.1266625

10.1080/10428194.2016.1266625

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27967292 AND SRC:MED&resulttype=core&format=json

release_oiiolow2kbg75p5cs3g7w2g4de

29 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oiiolow2kbg75p5cs3g7w2g4de

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference